Evidence map›Paper›PMID 40802086›Full record

ArticleAnnals of surgical oncology2026

The Impact of Adjuvant Radiotherapy Administration on Disease-Specific Survival in Patients with Parathyroid Carcinoma.

Hala Al Asadi, Haythem Najah, Jacques A Greenberg, Benjamin Greenspun, Niloufar Salehi, Dilay Aykan, Brendan M Finnerty, Thomas J Fahey, Rasa Zarnegar

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Critical Insights into Parathyroid Cancer.Journal of cancer science and clinical therapeutics · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hala Al AsadiDivision of Endocrine and Minimally Invasive Surgery, Department of Surgery, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA.
Haythem NajahDepartment of Digestive and Endocrine Surgery, Orleans University Hospital Center, Orleans, France.
Jacques A GreenbergDivision of Endocrine and Minimally Invasive Surgery, Department of Surgery, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA.
Benjamin GreenspunDivision of Endocrine and Minimally Invasive Surgery, Department of Surgery, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA.
Niloufar SalehiDivision of Endocrine and Minimally Invasive Surgery, Department of Surgery, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA.
Dilay AykanDepartment of Surgical Oncology and Endocrine Surgery, University Medical Center Utrecht, Utrecht, Netherlands.
Brendan M FinnertyDivision of Endocrine and Minimally Invasive Surgery, Department of Surgery, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA.
Thomas J FaheyDivision of Endocrine and Minimally Invasive Surgery, Department of Surgery, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA.
Rasa ZarnegarDivision of Endocrine and Minimally Invasive Surgery, Department of Surgery, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA. Raz2002@med.cornell.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe effect of adjuvant radiotherapy (AR) on disease-specific survival (DSS) in patients with parathyroid carcinoma remains unclear. We explored the impact of AR on DSS.

methodsPatients with parathyroid carcinoma were identified in SEER and categorized based on AR administration. To address confounding factors affecting the nonrandom allocation of radiotherapy, we conducted propensity score matching. We then employed Kaplan-Meier survival analysis to estimate DSS.

resultsIn total, 549 patients were included, with 64 (11.6%) receiving AR. Those who received AR had larger tumors, measuring 3.2 (interquartile range 2.3-4.5) cm compared with 2.7 (interquartile range 1.8-3.5) cm than those who did not receive AR (p = 0.01). Patients who received AR exhibited improved 10- (90.3% vs. 72.2%, p = 0.02) and 20 year DSS (90% vs. 68%, p = 0.03). Our multivariable Cox regression confirmed that patients who did not receive AR had poorer DSS [3.2, 95% CI 1.3-10.1]. Furthermore, non-Hispanic ethnicity [Hispanic patients: 0.13, 95% CI 0.007-0.7], extraparathyroidal extension (EPE) [2.7, 95% CI 1.1-6.9], and positive lymph node status [10.2, 95% CI 1.6-47.8] were linked to diminished DSS.

conclusionsUsing propensity-score matching in a large database, AR in patients with parathyroid carcinoma was associated with improved DSS compared with matched patients who did not receive AR. Notably, the lack of AR administration was identified as an independent factor linked to poorer DSS [3.2, 95% CI 1.3-10.1]. These findings indicate that AR should be considered by clinicians when dealing with these rare tumors and prospective studies are warranted to further assess its role.

Indexed as

Parathyroid NeoplasmsAdultAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisPropensity ScoreRadiotherapy, AdjuvantSEER ProgramSurvival RateAdjuvant radiotherapyDisease-specific survivalParathyroid cancerPropensity score matchingSEER

Identifiers

PMID40802086

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.